Skip to main content
Clinical Trials/EUCTR2018-004166-33-IT
EUCTR2018-004166-33-IT
Active, not recruiting
Phase 1

ORGAN SPARING FOR LOCALLY ADVANCED RECTAL CANCER AFTER NEOADJUVANT TREATMENT FOLLOWED BY ELECTROCHEMOTHERAPY

ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE0 sites70 target enrollmentDecember 11, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
Enrollment
70
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 11, 2018
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • a)Male or female patients aged \> 18 years
  • b)Histological confirmation of rectal adenocarcinoma
  • c)Patients undergoing neoadjuvant treatment for locally advanced tumor of the rectum with confirmed major clinical response after neoadjuvant treatment
  • d)Rectal tumor up to 12 cm from the external anal margin
  • e)Patients must be willing to comply with the study protocol and give their informed written consent.
  • f)Patients with an ECOG status performance \<3
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 40

Exclusion Criteria

  • a)Age less than 18 years
  • b)Patients with neoplasia more than 12 cm from the anal margin
  • c)Patients with stable disease or disease progression after neoadjuvant treatment
  • d)Patients, who for medical reasons, cannot be given bleomycin
  • e)Lesions not suitable for ECT (bony invasion, large vessels infiltration, etc.);
  • f)Acute lung infection;
  • g)Symptoms of poor lung function;
  • h)Non correctable severe coagulation disorders;
  • i)Previous allergic reactions to bleomycin;
  • j)Previous cumulative dose of 250 mg/m2 of bleomycin exceeded;

Outcomes

Primary Outcomes

Not specified

Similar Trials